ASX:BDXPharmaceuticals, Biotechnology & Life SciencesBiotechnology
BCAL Diagnostics Ltd
$0.079
+$0.003 (+3.95%)
Day Range
$0.076 – $0.079
52 Week Range
$0.052 – $0.155
Volume
84.22K
Avg Volume (10D)
53.02K
Market Cap
$29.13M
Price Chart
Market Statistics
Open$0.076
Previous Close$0.076
Day High$0.079
Day Low$0.076
52 Week High$0.155
52 Week Low$0.052
Valuation
Market Cap29.13M
Shares Outstanding368.68M
Price to Book11.20
Trading Activity
Volume84.22K
Value Traded6.40K
Bid$0.075 × 50,000
Ask$0.082 × 30,000
Performance
1 Day0.00%
5 Day7.04%
13 Week-10.59%
52 Week16.92%
YTD-27.62%
Technical Indicators
RSI (14)54.00
50-Day SMA$0.076
200-Day SMA$0.092
Latest News
Biotechnology
BCAL Diagnostics Develops Blood Test for Breast Cancer Recurrence Monitoring
BCAL Diagnostics launches BREASTEST Monitor—blood test to monitor post-treatment breast cancer recurrence; 91% sensitivity, 95% NPV.
Biotechnology
BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests
BCAL Diagnostics expands access to early cancer blood tests by embedding GP referral forms in major clinical software; launches EarlyDetection telehealth.
Biotechnology
BCAL Diagnostics Accelerates Avantect Rollout via Sonic Healthcare and Healius Partnerships
BCAL Diagnostics speeds Avantect rollout as Sonic Healthcare and Healius expand access to pancreatic/ovarian cancer tests nationwide.
Biotechnology
BCAL Diagnostics on Track for Australian Launch of Aventect Pancreatic and Ovarian Cancer Tests
BCAL Diagnostics (ASX: BDX) is on track to launch the cutting-edge Avantect pancreatic and ovarian cancer tests onto the Australian market in the new year.